Publications by authors named "Allison LaHood"
Background: In 2019, the World Health Organization called for operational research on all-oral shortened regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We report safety and effectiveness of three 9-month all-oral regimens containing bedaquiline (Bdq), linezolid (Lzd), and levofloxacin (Lfx) and reinforced with cycloserine (Cs) and clofazimine (Cfz), delamanid (Dlm) and pyrazinamide (Z), or Dlm and Cfz.
Methods: We conducted a prospective cohort study of patients initiating treatment for pulmonary MDR/RR-TB under operational research conditions at public health facilities in Kazakhstan.
Background: Few studies have examined the burden of postacute sequelae of coronavirus disease 2019 (COVID-19) (PASC) in low- and middle-income countries. We sought to characterize PASC with self-reported questionnaires and clinical examinations of end-organ function in Lima, Peru.
Methods: From January to July 2021, we recruited participants at least 8 weeks after COVID-19 diagnosis from a case registry in Lima, Peru.
Background: Tuberculosis, like COVID-19, is most often a pulmonary disease. The COVID-19 pandemic has severely disrupted tuberculosis services in myriad ways: health facility closures, lockdowns, travel bans, overwhelmed healthcare systems, restricted export of antituberculous drugs, etc. The effects of the shared risk on outcomes of the two diseases is not known, particularly for the first year of the pandemic, during the period before COVID-19 vaccines became widely available.
View Article and Find Full Text PDFArticle Synopsis
- Tuberculosis (TB), HIV, and hepatitis C virus (HCV) disproportionately affect marginalized populations, but TB has seen fewer new drug approvals in recent decades despite recent developments.
- Regulatory pathways aimed at improving drug approval for urgent health needs have not significantly sped up the approval process for TB drugs, which took much longer to reach the market compared to HIV and HCV drugs.
- Analysis revealed that TB drugs had fewer trial participants and longer development timelines, raising concerns about the differences in drug approval processes and their implications for treatment guidelines.